CVE-2022-47376The Alaris Infusion Central software, versions 1.1 to 1.3.2, may contain a recoverable password after the installation.
Updated under an hour ago ()
Does this affect you?
It affects bd alaris_infusion_central. Add what you run to find out whether that includes you.
EPSS puts the chance of exploitation in the next 30 days at 0.16%, higher than 5% of scored CVEs.
Do this next
Free account, 1 product
The Alaris Infusion Central software, versions 1.1 to 1.3.2, may contain a recoverable password after the installation. No patient health data is stored in the database, although some site installations may choose to store personal data.
- CVSS
- 7.3 HIGH (v3.1, CISA ADP)CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:L
- Weakness (CWE)
- CWE-257
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- 0.16% (percentile 5)
- Assigned by
- BD
- NVD analysis
- Modified
- Record last updated
- Jan 3, 2025
- First seen by InfoSec Signals
- Oct 12, 2026
Affected products
bd alaris_infusion_central bd:alaris_infusion_central | from 1.1 through 1.3.2 | NVD |
References
- https://www.bd.com/en-us/about-bd/cybersecurity/bulletin/alaris-infusion-central-recoverable-password-vulnerabilityvendor-advisory
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.